Aberrant tau inside neurons is a key driver of Alzheimer’s disease, but nearly all the therapies in development to target it can only capture the small amount that floats outside of them. A new animal study reports impressive results in clearing aberrant tau inside neurons and rejuvenating cognitive function, opening up an important new front in damage-repair strategies for maintaining the aging brain.
Several pharma companies are currently running clinical trials on damage-repair therapies targeting damaged forms of the protein tau to combat Alzheimer’s disease. But these AmyloSENS therapies only reach tau in the fluid outside of neurons, when what we need is to clear damaged tau inside of them. Fortunately, researchers are beginning to use mRNA — the same revolutionary biotechnology platform of the best COVID vaccines — to develop new LysoSENS therapies to do just that.
Sign up to stay informed about the latest news and opportunities with SRF!
Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.
© 2024 SENS Research Foundation – ALL RIGHTS RESERVED
Sign up to stay informed about the latest news and opportunities with SRF!
Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.
© 2024 SENS Research Foundation – ALL RIGHTS RESERVED
